Femasys Announces Financial Results for Quarter Ended September 30, 2026 and Provides Corporate Update
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Femasys (NASDAQ: FEMY) reported third-quarter sales of $404,597, down 44.5% year over year, alongside a wider net loss. U.S. sales rose to $347,039 from $336,594. Net loss reached $4,564,815 versus $4,194,821, while loss per share narrowed to $0.53 from $2.05. Nine-month sales fell 21.5% to $1,161,313, and net loss narrowed to $8,187,810 from $14,677,582.
A completed $30 million private placement supports U.S. commercial hiring and the FemBloc pivotal trial. Total proceeds could reach up to $85 million upon full cash exercise of warrants. Cash was $23,913,946 at September 30, 2026, versus $9,266,353 at December 31, 2025. FemBloc received FDA approval for a modular premarket approval submission approach, and actively enrolling FINALE trial sites doubled to twelve. New patents cover its blended polymer component. Femasys also announced fertility portfolio partnerships with UNC Health and Minnesota Women’s Care.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointCompleted $30 million private placement funds U.S. commercial team expansion and the FemBloc pivotal trial. 2.6× market cap
- Moderate pointNine-month net loss narrowed to $8,187,810 from $14,677,582; loss per share narrowed to $1.59 from $9.25.
- Moderate pointFDA approval permits a modular premarket approval submission approach for FemBloc.
- Minor point. Forward-looking: it has not happened yet and may not happen.Potential total financing proceeds reach up to $85 million upon full cash exercise of warrants.
- Minor pointCash and cash equivalents rose to $23,913,946 at September 30, 2026, from $9,266,353 at December 31, 2025.
15 minor points
- Minor pointQ3 U.S. sales increased to $347,039 from $336,594 a year earlier.
- Minor pointNine-month U.S. sales increased to $1,038,997 from $1,015,168 a year earlier.
- Minor pointFINALE actively enrolling trial sites doubled to twelve to support FemBloc U.S. approval.
- Minor pointFemBloc patents issued in U.S. and international markets expand protection for the blended polymer component.
- Minor point. Forward-looking: it has not happened yet and may not happen.Commercial recruitment is underway following financing; Femasys expects territorial deployment to broaden adoption and drive revenue growth.
- Minor pointNine-month research and development expenses decreased 9.8% to $5,199,206 from $5,764,923.
- Minor pointQ3 sales and marketing expenses declined to $943,002 from $1,143,805 a year earlier.
- Minor pointCost of sales, excluding depreciation fell year over year: Q3 to $187,496 from $293,838; nine months to $488,538 from $569,275.
- Minor pointInterest expense fell year over year: Q3 to $200,415 from $532,073; nine months to $563,072 from $1,483,022.
- Minor pointInterest income rose year over year: Q3 to $85,610 from $17,315; nine months to $155,131 from $53,488.
- Minor pointNine-month fair-value gains were $1,732,413 on the conversion option liability and $4,228,000 on warrant liabilities.
- Minor pointDepreciation and amortization declined year over year: Q3 to $77,091 from $85,697; nine months to $242,172 from $256,835.
- Minor pointOther expense fell to zero in Q3 and nine months, versus $26,295 and $286,295, respectively, a year earlier.
- Minor pointTotal liabilities declined to $8,059,496 at September 30, 2026, from $14,854,875 at December 31, 2025.
- Minor pointStockholders’ equity increased to $27,028,162 at September 30, 2026, from $5,869,302 at December 31, 2025.
Negative
- Major pointCommon shares outstanding increased to 8,656,277 at September 30, 2026, from 2,980,254 at December 31, 2025.
- Moderate pointQ3 sales declined 44.5% year over year to $404,597 from $729,394.
- Moderate pointQ3 net loss widened to $4,564,815 from $4,194,821, although loss per share narrowed to $0.53 from $2.05.
- Minor pointNine-month sales declined 21.5% year over year to $1,161,313 from $1,479,926.
- Minor point. Forward-looking: it has not happened yet and may not happen.Financing warrants create potential additional dilution if exercised.
9 minor points
- Minor pointQ3 research and development expenses increased 40.6% to $1,942,927 from $1,382,022.
- Minor pointNine-month sales and marketing expenses increased to $3,552,755 from $3,037,349 a year earlier.
- Minor pointGeneral and administrative expenses rose year over year: Q3 to $1,704,091 from $1,477,800; nine months to $5,418,059 from $4,817,485.
- Minor pointOperating losses widened year over year: Q3 to $4,450,010 from $3,653,768; nine months to $13,739,417 from $12,965,941.
- Minor point. Forward-looking: it has not happened yet and may not happen.International FemBloc reorders are expected after distributors complete post-market studies using existing inventory.
- Minor pointConvertible notes payable, net rose to $3,717,653 at September 30, 2026, from $3,178,864 at December 31, 2025.
- Minor pointCurrent note payable reached $292,229 at September 30, 2026, versus none at December 31, 2025.
- Minor pointAccumulated deficit increased to $154,013,954 at September 30, 2026, from $145,826,144 at December 31, 2025.
- Minor pointNine-month income taxes shifted to $865 expense from a $4,188 benefit a year earlier.
News Explained
The balance sheet reports 8,656,277 common shares outstanding on
Key Figures
- Completed private placement
- $30 million
- Completed in mid-August 2026
- Potential warrant proceeds
- Up to $85 million
- Upon full cash exercise of warrants
- Q3 overall sales
- 44.5% decrease to $404,597 from $729,394
- Quarter ended September 30, year over year
- Q3 U.S. sales
- $347,039 from $336,594
- Quarter ended September 30, year over year
- Q3 net loss
- $4,564,815 from $4,194,821
- Quarter ended September 30, year over year
- Nine-month net loss
- $8,187,810 from $14,677,582
- Nine months ended September 30, year over year
- Cash and cash equivalents
- Approximately $23.9 million
- As of September 30, 2026
- Actively enrolling FINALE sites
- 12 sites, doubled
- FemBloc pivotal trial
Previous Earnings Reports
-
Completed $30 million placement; six-month sales rose and net loss narrowed.
-
Q1 sales increased, with net income and early FemaSeed adoption reported.
-
Q3 sales increased year over year alongside regulatory milestones and financing.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
private placement financial
warrants financial
pivotal trial medical
premarket approval regulatory
post-market studies medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ATLANTA, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announces its financial results for the quarter ended September 30, 2026 and provides a corporate update.
Corporate Highlights from 3Q 2026 to date
- Completed
$30 million private placement with potential total proceeds of up to$85 million upon full cash exercise of warrants, to build-out the U.S. commercial team needed to support revenue growth following recent availability of the FemaSeed® fertility portfolio to OB/GYNs, and to fund the FemBloc® pivotal trial to support U.S. approval. - Highlights for the FemaSeed Fertility Portfolio (Diagnostics: FemVue® for her and SpermVueTM for him; first-step treatment: FemaSeed and FemSperm®):
- Announced a partnership with both UNC Health and Minnesota Women’s Care to introduce the entire portfolio across its OB/GYN practice locations.
- Announced a partnership with CapexMD to expand patient access through financing solutions and SandsRx Pharmacy for medications to support treatment timing.
- Highlights for FemBloc Permanent Birth Control:
- Issuance of patents in the U.S. and key international markets that expand intellectual property protection for the blended polymer component.
- Received FDA approval of the modular premarket approval (PMA) submission approach.
- Announced the number of actively enrolling sites in the FINALE trial to support U.S. approval doubled to twelve sites.
“We maintained a lean team and tightly managed resources as we prioritized financing from long-term institutional investors. Closing the
Financial Results for Quarter Ended September 30, 2026
- Sales in the U.S. increased slightly to
$347,039 in 2026 from$336,594 in 2025, while overall sales decreased by$324,797 , or44.5% , to$404,597 from$729,394 . The overall decline was anticipated and reflects the timing of international FemBloc orders, consistent with distributors’ customary bulk-ordering practices. Distributors are utilizing existing inventory to support FemBloc post-market studies, with reorders expected after those studies are completed. - Research and development expenses increased by
$560,905 , or40.6% , to$1,942,927 in 2026 compared to$1,382,022 in 2025, primarily reflecting the transition of development products into inventory to support commercialization during 2025, and increased clinical costs and compensation costs during 2026. - Net loss was
$4,564,815 , or ($0.53 ) per basic and diluted share attributable to common stockholders, for the quarter ended September 30, 2026, compared to a net loss of$4,194,821 , or ($2.05 ) per basic and diluted share attributable to common stockholders, for the quarter ended September 30, 2025.
Financial Results for Nine Months Ended September 30, 2026
- Sales in the U.S. increased slightly to
$1,038,997 in 2026 from$1,015,168 in 2025, while overall sales decreased by$318,613 , or21.5% , to$1,161,313 from$1,479,926 . The overall decline was anticipated and reflects the timing of international FemBloc orders, consistent with distributors’ customary bulk-ordering practices. Distributors are utilizing existing inventory to support FemBloc post-market studies, with reorders expected after those studies are completed. - Research and development expenses decreased by
$565,717 , or9.8% , to$5,199,206 in 2026 compared to$5,764,923 in 2025, primarily reflecting lower compensation costs, regulatory fees and outside consultant costs, partially offset by increased clinical costs and material and development costs. - Net loss was
$8,187,810 , or ($1.59 ) per basic and diluted share attributable to common stockholders, for the nine months ended September 30, 2026, compared to a net loss of$14,677,582 , or ($9.25 ) per basic and diluted share attributable to common stockholders, for the nine months ended September 30, 2025. - Cash and cash equivalents as of September 30, 2026, were approximately
$23.9 million and the Company had an accumulated deficit of approximately$154.0 million .
For more information, please refer to the Company’s Form 10-Q filed November 13, 2026, which can be accessed on the SEC website.
| FEMASYS INC. | |||||||||||
| Condensed Balance Sheets | |||||||||||
| (unaudited) | |||||||||||
| Assets | September 30, 2026 | December 31, 2025 | |||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 23,913,946 | 9,266,353 | ||||||||
| Accounts receivable, net | 233,778 | 616,600 | |||||||||
| Inventory | 6,166,371 | 5,740,249 | |||||||||
| Prepaid and other current assets | 893,098 | 833,133 | |||||||||
| Total current assets | 31,207,193 | 16,456,335 | |||||||||
| Property and equipment, at cost: | |||||||||||
| Leasehold improvements | 1,238,886 | 1,238,886 | |||||||||
| Office equipment | 91,610 | 78,155 | |||||||||
| Furniture and fixtures | 424,586 | 417,876 | |||||||||
| Machinery and equipment | 3,125,855 | 3,065,713 | |||||||||
| Construction in progress | 991,124 | 897,885 | |||||||||
| 5,872,061 | 5,698,515 | ||||||||||
| Less accumulated depreciation | (3,991,222 | ) | (3,802,940 | ) | |||||||
| Net property and equipment | 1,880,839 | 1,895,575 | |||||||||
| Long-term assets: | |||||||||||
| Lease right-of-use assets, net | 952,796 | 1,297,121 | |||||||||
| Intangible assets, net of accumulated amortization | 99,902 | 134,914 | |||||||||
| Other long-term assets | 946,928 | 940,232 | |||||||||
| Total long-term assets | 1,999,626 | 2,372,267 | |||||||||
| Total assets | $ | 35,087,658 | 20,724,177 | ||||||||
| (continued) | |||||||||||
| FEMASYS INC. | |||||||||||
| Condensed Balance Sheets | |||||||||||
| (unaudited) | |||||||||||
| Liabilities and Stockholders’ Equity | September 30, 2026 | December 31, 2025 | |||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 1,958,546 | 1,830,124 | ||||||||
| Accrued expenses | 855,377 | 1,265,773 | |||||||||
| Note payable | 292,229 | — | |||||||||
| Clinical holdback – current portion | 29,250 | 52,644 | |||||||||
| Operating lease liabilities – current portion | 465,960 | 487,624 | |||||||||
| Total current liabilities | 3,601,362 | 3,636,165 | |||||||||
| Long-term liabilities: | |||||||||||
| Clinical holdback – long-term portion | 58,179 | 52,370 | |||||||||
| Convertible notes payable, net | 3,717,653 | 3,178,864 | |||||||||
| Conversion option liability | — | 2,014,000 | |||||||||
| Warrants liabilities | — | 4,943,000 | |||||||||
| Operating lease liabilities – long-term portion | 682,302 | 1,030,476 | |||||||||
| Total long-term liabilities | 4,458,134 | 11,218,710 | |||||||||
| Total liabilities | 8,059,496 | 14,854,875 | |||||||||
| Commitments and contingencies | |||||||||||
| Stockholders’ equity: | |||||||||||
| Common stock, | |||||||||||
| 8,662,139 shares issued and 8,656,277 shares outstanding as of | |||||||||||
| September 30, 2026; and 2,986,116 shares issued | |||||||||||
| and 2,980,254 shares outstanding as of December 31, 2025 | 8,662 | 2,986 | |||||||||
| Treasury stock, 5,862 common shares | (60,000 | ) | (60,000 | ) | |||||||
| Warrants | 19,023,695 | 5,246,150 | |||||||||
| Additional paid-in capital | 162,069,759 | 146,506,310 | |||||||||
| Accumulated deficit | (154,013,954 | ) | (145,826,144 | ) | |||||||
| Total stockholders’ equity | 27,028,162 | 5,869,302 | |||||||||
| Total liabilities and stockholders' equity | $ | 35,087,658 | 20,724,177 | ||||||||
| FEMASYS INC. | |||||||||||||||||
| Condensed Statements of Operations | |||||||||||||||||
| (unaudited) | |||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||
| Sales | $ | 404,597 | 729,394 | 1,161,313 | 1,479,926 | ||||||||||||
| Cost of sales (excluding depreciation expense) | 187,496 | 293,838 | 488,538 | 569,275 | |||||||||||||
| Operating expenses: | |||||||||||||||||
| Research and development | 1,942,927 | 1,382,022 | 5,199,206 | 5,764,923 | |||||||||||||
| Sales and marketing | 943,002 | 1,143,805 | 3,552,755 | 3,037,349 | |||||||||||||
| General and administrative | 1,704,091 | 1,477,800 | 5,418,059 | 4,817,485 | |||||||||||||
| Depreciation and amortization | 77,091 | 85,697 | 242,172 | 256,835 | |||||||||||||
| Total operating expenses | 4,667,111 | 4,089,324 | 14,412,192 | 13,876,592 | |||||||||||||
| Loss from operations | (4,450,010 | ) | (3,653,768 | ) | (13,739,417 | ) | (12,965,941 | ) | |||||||||
| Other income (expense): | |||||||||||||||||
| Interest income | 85,610 | 17,315 | 155,131 | 53,488 | |||||||||||||
| Change in fair value of Conversion Option liability | — | — | 1,732,413 | — | |||||||||||||
| Change in fair value of Warrants liabilities | — | — | 4,228,000 | — | |||||||||||||
| Interest expense | (200,415 | ) | (532,073 | ) | (563,072 | ) | (1,483,022 | ) | |||||||||
| Other expense | — | (26,295 | ) | — | (286,295 | ) | |||||||||||
| Total other income (expense), net | (114,805 | ) | (541,053 | ) | 5,552,472 | (1,715,829 | ) | ||||||||||
| Loss before income taxes | (4,564,815 | ) | (4,194,821 | ) | (8,186,945 | ) | (14,681,770 | ) | |||||||||
| Income tax expense (benefit) | — | — | 865 | (4,188 | ) | ||||||||||||
| Net loss | $ | (4,564,815 | ) | (4,194,821 | ) | (8,187,810 | ) | (14,677,582 | ) | ||||||||
| Net loss attributable to common stockholders | $ | (4,564,815 | ) | (4,194,821 | ) | (8,187,810 | ) | (14,677,582 | ) | ||||||||
| Basic and diluted loss per share | $ | (0.53 | ) | (2.05 | ) | (1.59 | ) | (9.25 | ) | ||||||||
| Weighted-average common shares and pre-funded warrants outstanding, basic and diluted | 8,660,381 | 2,050,761 | 5,136,109 | 1,586,992 | |||||||||||||
About Femasys Inc.
Femasys is a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide. The Company is focused on commercializing its fertility portfolio, led by FemaSeed® Intratubal Insemination, together with complementary diagnostic and sperm preparation products, in the U.S. and key international markets. Femasys is also advancing FemBloc®, its non-surgical, in-office permanent birth control solution, toward U.S. FDA approval through the ongoing FINALE pivotal trial (NCT05977751). FemBloc received regulatory approvals in Europe, the UK and New Zealand in 2025, supporting commercialization through strategic partnerships in select international markets. Femasys’ portfolio is supported by broad intellectual property protection and clinical data demonstrating favorable safety, encouraging effectiveness results, and high patient and practitioner satisfaction.
Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
IR@femasys.com
Media@femasys.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Femasys FEMY’s third-quarter 2026 sales and earnings?
Femasys reported sales of $404,597 and a net loss of $4,564,815 for the quarter ended September 30, 2026. Sales fell 44.5% from $729,394 a year earlier. Net loss widened from $4,194,821, while basic and diluted loss per share narrowed to $0.53 from $2.05.
How much did Femasys raise in its private placement, and what will it fund?
Femasys completed a $30 million private placement to build its U.S. commercial team and fund the FemBloc pivotal trial supporting U.S. approval. Potential total proceeds could reach up to $85 million upon full cash exercise of warrants.
Why did Femasys international FemBloc sales decline in 2026?
Femasys attributes the overall sales decline to international FemBloc order timing, consistent with distributors’ customary bulk-ordering practices. Distributors are using existing inventory for FemBloc post-market studies, with reorders expected after those studies are completed.